Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014

N Turner; N Pierse; Q S Huang; S Radke; A Bissielo; M G Thompson; H Kelly; Collective on behalf of the SHIVERS investigation team

doi:10.2807/1560-7917.ES2014.19.42.20934

Rapid communications Open Access

Like 0

Download

Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014
N Turner¹ , N Pierse² , Q S Huang³ , S Radke^1,3 , A Bissielo³ , M G Thompson⁴ , H Kelly^5,6 , Collective on behalf of the SHIVERS investigation team⁷
View Affiliations Hide Affiliations

Affiliations: ¹ The University of Auckland, Auckland, New Zealand ² University of Otago, Wellington, New Zealand ³ Institute of Environmental Science and Research, Wellington, New Zealand ⁴ Influenza Division, United States Centers for Disease Control and Prevention, Atlanta, GA, United States ⁵ Australian National University, Canberra, Australia ⁶ Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia ⁷ Members of the team are listed at the end of the article

Correspondence:
N Turner
n.turner auckland.ac.nz
View Citation Hide Citation

Citation style for this article: Turner N, Pierse N, Huang Q S, Radke S, Bissielo A, Thompson M G, Kelly H, on behalf of the SHIVERS investigation team Collective. Interim estimates of the effectiveness of seasonal trivalent inactivated influenza vaccine in preventing influenza hospitalisations and primary care visits in Auckland, New Zealand, in 2014. Euro Surveill. 2014;19(42):pii=20934. https://doi.org/10.2807/1560-7917.ES2014.19.42.20934 Received: 07 Oct 2014

Abstract

We present preliminary results of influenza vaccine effectiveness (VE) in New Zealand using a case test-negative design for 28 April to 31 August 2014. VE adjusted for age and time of admission among all ages against severe acute respiratory illness hospital presentation due to laboratory-confirmed influenza was 54% (95% CI: 19 to 74) and specifically against A(H1N1)pdm09 was 65% (95% CI:33 to 81). For influenza-confirmed primary care visits, VE was 67% (95% CI: 48 to 79) overall and 73% (95% CI: 50 to 85) against A(H1N1)pdm09.